Cancer-Fighting CAR-T cells take on tough kidney disease in first human trial

This early-phase trial tests whether a personalized immune cell therapy called CAR-T can safely treat a severe, hard-to-control kidney condition called refractory membranous nephropathy. Five adults with confirmed disease will receive a single infusion of engineered cells after mild chemotherapy, then be monitored closely for side effects and kidney improvement over one year. The main goal is to check safety, but researchers will also see if the treatment reduces protein in the urine and improves kidney function.